<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals Ltd (BSE Scrip Code: 539730) has filed an initial disclosure with the stock exchange confirming its status as a 'Large Corporate' under SEBI circulars dated October 19, 2023 and November 26, 2018. The company has stated that it does not meet the criteria specified in these circulars and therefore does not qualify as a Large Corporate. This means the company is not required to mandatorily raise a minimum portion of its funding through debt securities from the market. The disclosure was signed by Managing Director Fredun Nariman Medhora on April 9, 2025.
This is a routine regulatory compliance filing and is largely neutral for shareholders. It simply confirms the company is below the threshold to be classified as a Large Corporate, meaning no mandatory debt issuance obligation applies. It does not indicate any change in business operations or financial health.